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Abstract
Background:  Glucocorticoid hormones (GCs) induce apoptosis of leukemic T-cells by
transcriptional regulation via the GC receptor, GR. In the human leukemic CEM cell culture model,
RCAN1 has been identified as one of the genes that is specifically upregulated only in the GC-
sensitive CEM C7-14 cells, but not in the GC-resistant CEM-C1-15 sister cells in correlation with
GC-evoked apoptosis. RCAN1 gene encodes two major protein isoforms of the regulator of
calcineurin (RCAN1), RCAN1-1 and RCAN1-4 via alternative splicing of exons 1 and 4
respectively, to exons 5-7. Studies reported here evaluated the differential regulation and function
of the two transcripts and protein products of RCAN1 by the synthetic GC dexamethasone (Dex),
and by modulators of calcium signaling.
Results: Dex selectively upregulates transcript specific for RCAN 1-1 in glucocorticoid (GC)-
susceptible human leukemic CEM-C7-14 cells but not in GC-refractory CEM-C1-15 sister cells.
Expression of the second major transcript, RCAN1-4, is upregulated by [Ca2+]i inducers, thapsigargin
and A23187, but not by Dex, suggesting a mutually exclusive regulatory pathway for both RCAN1
transcripts. GC-mediated upregulation of RCAN1-1 transcript and RCAN1-1 protein was kinase
dependent, and was blocked by staurosporine and the p38 MAP kinase inhibitor SB 202190.
RCAN1-1 coimmunoprecipitates with calcineurin PP3C and Dex-mediated RCAN1-1 upregulation
correlated with reduction in calcineurin PP3C activity.
Conclusion: Data presented here suggest that GCs specifically upregulate RCAN1-1 transcript and
protein while inducers of [Ca2+]i selectively upregulate RCAN1-4. GC-mediated increase in RCAN1-
1 abundance and binding possibly inhibits calcineurin activity and modulates apoptosis in CEM-C7-
14 cells.
Background
Glucocorticoids (GCs) are effective antileukemic agents
because of their ability to induce growth arrest and evoke
apoptosis of normal thymocytes, immature peripheral T
cells and many leukemic cells [1,2]. GCs activate the GC
receptor (GR), a transcription factor that regulates expres-
sion of genes involved in modulating GC-induced actions
such as immunosuppression, anti-inflammation and
apoptosis [3]. Several laboratories have analyzed changes
in gene expression profiles induced by GCs in an effort to
identify candidate genes modulating GC-evoked apopto-
sis of leukemic lymphoid cells. Microarray analysis of a
pair of GC-sensitive and -resistant human leukemic T-cell
sister clones, CEM-C7-14 and CEM-C1-15, respectively,
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has shown that RCAN1 (Regulator of Calcineurin 1) gene,
(also called Adapt78  or  DSCR1) [4,5], whose protein
product is RCAN1 (also called Calcipressin1), is one of
the genes selectively upregulated by GCs only in CEM-C7-
14 cells [6,7]. RCAN1 has been shown to bind to and
modulate the activity of the catalytic subunit of the cal-
cium-dependent phosphatase, calcineurin (PP3C) [4,8].
Calcineurin plays an important role in regulation of T-cell
activation and apoptosis [9,10].
The RCAN1 locus is at chromosome 21q22.12 in humans,
close to the Down Syndrome Critical region, and has been
implicated in the pathophysiology of Down Syndrome
and Alzheimer's disease [11,13], has been shown to regu-
late vascular function [14] and has been proposed to play
an important role in the brain [15]. Alternative splicing
and/or promoter usage results in multiple isoforms from
the seven exons that make up the RCAN1 gene. The two
major isoforms identified in most tissues are designated
isoform 1 (exons 1+ 5-7; RCAN1-1) and isoform 4 (exons
4 + 5-7; RCAN1-4) [16]. These isoforms may be differen-
tially upregulated in response to various stress signals,
including calcium [17,18]. Calcineurin-dependent upreg-
ulation of RCAN1-4  (isoform 4) has been reported to
occur through an alternative promoter in intron 3, which
includes a cluster of 15 NFAT binding sites [19]. RCAN1-
1 expression is upregulated in response to oxidant- and
Ca2+-induced stress [20,21], and various reports suggest
either a cytoprotective [20] or apoptotic [22,23] function
for it. A recent knock out mouse model suggests that
RCAN1 functions as a facilitator of calcineurin activity in
vivo [24].
Phosphorylation of these isoforms at conserved serine res-
idues has been shown to regulate their activity [25,27].
Unphosphorylated RCAN1 has been reported to bind to
and inhibit calcineurin activity, serving as a feedback
inhibitor of calcium signaling [12], while phosphoryla-
tion of RCAN1 has been shown to render it incapable of
binding to calcineurin, thereby increasing calcineurin
activity [27,28]. Indeed, phosphorylation of one or both
serine residues in a 13-amino acid synthetic peptide atten-
uated in vitro inhibition of calcineurin activity [17]. Para-
doxically, exogenous or over expressed RCAN1-1
phosphorylation has been shown to enhance calcineurin
binding and inhibition [26]. Thus RCAN1 has been
reported to both positively and negatively regulate cal-
cineurin activity in various models. RCAN1 phosphoryla-
tion has also been shown to block its degradation and
increase soluble and insoluble levels of RCAN1 in neuro-
nal cells [29]
In studies presented here, we show that transcript and
protein levels of isoform 1 of RCAN1 are selectively upreg-
ulated by GCs, and that GCs promote accumulation of an
apparently unphosphorylated form of RCAN1-1, which is
capable of binding calcineurin. Since GC mediated
changes in RCAN1 expression and PP3C activity are
restricted to the apoptosis-susceptible CEM subclone
CEM-C7-14, and do not occur in the GC-resistant sub-
clone CEM-C1-15, we deduce that RCAN1-1 may modu-
late GC-dependent calcineurin activity and GC- evoked
apoptosis of leukemic lymphocytes.
Results
Microarray analysis and Northern hybridization studies
have previously suggested GC-dependent upregulation of
RCAN1 transcript levels occurs specifically in CEM-C7-14
cells that are susceptible, but not in CEM-C1-15 cells
which are refractory, to GC-evoked apoptosis [6]. Studies
presented here further evaluate the GC-dependent regula-
tion of individual transcripts of RCAN1 isoforms.
Dex specifically upregulates RCAN1-1 transcript levels
The expression of total RCAN1, RCAN1-1 and RCAN1-4
specific transcripts was analyzed by reverse transcription
and quantitative real-time PCR of ethanol vehicle or 100
nM Dex treated CEM-C7-14 and CEM-C1-15 cells using
exon 5-, 1- and 4-specific forward primers, respectively
(Table 1). Representative raw amplification profiles (Fig-
ure 1A) and gels corresponding to total RCAN1, RCAN1-1
and  RCAN 1.4 (Figure 1B) are shown. To normalize
between samples, β-actin was amplified using specific
primers shown in Table 1, and used as a reference. Rela-
tive expression of each transcript was calculated using a
modification of the Pfaffl method [30] (Figure 1C). Total
RCAN1 and RCAN1-1 transcript levels were induced 15-
and 13-fold in CEM-C1-14 cells, but were not significantly
altered in CEM-C1-15 cells after 24 h treatment with Dex
(Figure 1C). Using a two sample t-test, the Dex response
in CEM-C7-14 cells was significant compared to CEM-C1-
15 cells (p < 0.015) for both total RCAN1 and RCAN1-1.
Table 1: PCR Primers
Transcript Forward Reverse Size
RCAN1 All 5'GGACATCACCTTTCAGTATT3' 5'TTCCTCTTCTTCCTCCTTCT3' 394 bp
RCAN1-1 5'ACCATCGCCTGTCACCTGGA3' 5'GGTGATGTCCTTGTCATACGTCCT3' 96 bp
RCAN1-4 5'CTCCCTGATTGCCTGTGTGG3' 5'TTCCTCTTCTTCCTCCTTCT3' 484 bp
β actin 5'TCATGAAGTGTGACGTTGACATCCGT3' 5'CTTAGAAGCATTTGCGGTGCACGATG3' 285 bp
RCAN1 All = total RCAN1. Forward primers for RCAN1 All, RCAN1-1 and RCAN1-4 correspond to exons 5, 1 and 4 respectively. A common 
reverse primer for RCAN1 All and RCAN1-4 corresponds to exon 7, while the reverse primer for RCAN1-1 corresponds to exon 5.Journal of Molecular Signaling 2009, 4:6 http://www.jmolecularsignaling.com/content/4/1/6
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Basal expression of RCAN1-4 was minimal in both cell
types, and was not affected by Dex treatment (Figure 1).
Calcium signaling upregulates RCAN1-4 but not RCAN1-1
Various reports suggest that RCAN1 expression is regu-
lated by intracellular calcium ([Ca2+]i) levels [17,21].
Since GCs upregulate [Ca2+]i levels in CEM cells in corre-
lation with apoptosis [31], we determined whether Dex-
dependent upregulation of RCAN1-1 was modulated by
calcium signaling. CEM-C7-14 cells were treated for 24 h
with either Dex or thapsigargin (TG; inducer of [Ca2+]i lev-
els) in the presence or absence of the calcium ionophore
A23187, or the calcineurin inhibitor cyclosporin A (CsA),
and expression of transcripts corresponding to total
RCAN1, RCAN1-1 and RCAN1-4  was evaluated by RT-
QPCR.  RCAN1-4  is a minor transcript compared to
RCAN1-1; therefore expression profiles of total RCAN1
(Figure 2A) correlated mostly with those of RCAN1-1 (Fig-
ure 2B) and any regulation of RCAN1-4 did not influence
total RCAN1 profiles. Dex-induced upregulation of total
RCAN1 and RCAN1-1 was partially inhibited by A23187
(p < 0.02 and 0.03 respectively), suggesting that Dex-
dependent induction of these transcripts was inhibited by
increases in [Ca2+]i  levels (Figures 2A and 2B). CsA
enhanced Dex-evoked induction of total RCAN1, but the
effect was not statistically significant. Expression of
RCAN1-4 was induced 200 and 18-fold, respectively by
500 nM TG and 150 nM A23187 (Figure 2C), suggesting
that RCAN1-4 expression was regulated via the calcium
signaling pathway. This was confirmed by the observation
that 600 nM CsA blunted TG-dependent induction of
RCAN1-4 (Figure 2C) (p < 0.003).
Dex upregulates RCAN1-1 protein levels
Cells treated with ethanol vehicle or 100 nM Dex for 24 h
were analyzed for RCAN1 protein expression by Western
GCs selectively upregulate RCAN1-1 specific transcript Figure 1
GCs selectively upregulate RCAN1-1 specific transcript: Total RNA extracted from cells treated with 100 nM Dex (D) 
or 0.15 ethanol (E) was subjected to reverse transcription reaction and analyzed by Real-time Q-PCR using primers specified in 
Table 1. Panel A: Raw amplification profiles of each RCAN1 specific transcript. Panel B: Gel electrophoresis of Real-time Q-
PCR products after 18-22 cycles. Panel C: Relative expression of each transcript was calculated using the Pfaffl method using 
β-actin as a reference.Journal of Molecular Signaling 2009, 4:6 http://www.jmolecularsignaling.com/content/4/1/6
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blotting using an antibody that recognizes the carboxyl
terminal of RCAN1, and therefore detects both RCAN1-1
and RCAN1-4. Accordingly, a fast migrating minor band
around 29 kDa representing RCAN1-4, and a 41 kDa
band representing RCAN1-1 were detected (Figure 3A).
One or two additional bands recognized by the antibody
in various experiments were found to be nonspecifically
interacting proteins, as demonstrated through the use of a
blocking peptide (Abgent, Cat # BP6315c) specific for the
antibody (Figure 3B). Preincubation of the antibody with
the blocking peptide competed out the two RCAN1
bands, while not affecting the ability of the antibody to
recognize the two nonspecific bands. The induction of
RCAN1-1 was minimal in CEM-C1-15 cells (Figure 3A).
Phosphorylation state of RCAN1-1
To determine whether RCAN1-1 was pohsphorylated, cell
lysates were treated with lambda phosphatase prior to
Western blotting (Figure 3B) to detect either RCAN1 or
Regulation of RCAN1-1 and RCAN1-4 expression by calcium  signaling Figure 2
Regulation of RCAN1-1 and RCAN1-4 expression by 
calcium signaling: CEM-C7-14 cells were treated for 24 h 
with either ethanol vehicle, Dex or 500 nM thapsigargin (TG) 
in the presence or absence of the calcineurin inhibitor 
cyclosporin A (CsA, 600 nM) or the calcium ionophore 
A23187 (150 nM). RT-QPCR analysis was performed as in 
Figure 1 for total RCAN1 (RCAN1 All, Panel A), RCAN1-1 
(Panel B) and RCAN1-4 (Panel C) using primers specified in 
Table 1. Data were normalized using β-actin as a reference, 
and fold induction was calculated using the Pfaffl method 
(28). Data presented are averages of 2-4 independent exper-
iments.
GCs induce RCAN1-1 protein levels in CEM-C7-14 Cells:  Panel A Figure 3
GCs induce RCAN1-1 protein levels in CEM-C7-14 
Cells: Panel A: CEM-C7-14 and CEM-C1-15 cells were 
treated with ethanol vehicle (E) or 100 nM Dex (D) for 24 h. 
Western blotting was performed on 50 μg protein extracts 
using RCAN1 antibody (Abgent # AP6315c), or β-actin spe-
cific antibody (Santa Cruz # sc-8432). Panel B: Lysates pre-
pared from ethanol (E) or Dex (D) treated CEM-C7-14 cells 
were subjected to Western blotting as in Panel A, but the 
antibody was preincubated for 1 h with or without blocking 
peptide (Abgent # BP6315c). Panel C: Lysates prepared 
from CEM-C7-14 cells treated with ethanol vehicle (E) or 
100 nM Dex (D) for 24 h were treated with lambda buffer 
alone or lambda phosphatase for 20 min prior to Western 
blotting with either RCAN1 antibody as in Panel A, or CREB 
antibody (Santa Cruz #sc-186) to detect phosphorylation 
state.Journal of Molecular Signaling 2009, 4:6 http://www.jmolecularsignaling.com/content/4/1/6
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CREB using appropriate antibodies. CREB shifted to a
faster migrating band, demonstrating a loss of phosphate
residues, and confirming successful phosphatase treat-
ment of the sample. The migration of RCAN1-1, or the rel-
ative abundance of the band was not affected by the
phosphatase treatment, suggesting that phosphatase treat-
ment did not alter its phosphorylation state. It is possible
that the gel is not capable of resolving small differences in
migration of phosphorylated and unphosphorylated
RCAN1-1. To test this hypothesis, lysates of ethanol or
Dex treated CEM-C7-14 cells were immunoprecipitated
with phospho-serine, phospho-threonine or phospho-
tyrosine specific antibodies coupled to Agarose beads.
None of these antibodies pulled down RCAN1-1(data not
shown), supporting the hypothesis that RCAN1-1 was not
phosphorylated.
Dex-evoked RCAN1-1 upregulation is kinase dependent
CEM-C7-14 cells were simultaneously treated with vari-
ous kinase inhibitors in the presence of either ethanol or
Dex, and processed for QPCR analysis (Figure 4A) or
Western blotting (Figure 4B) to determine whether GC-
mediated upregulation of RCAN1-1 transcript or protein
was kinase dependent. The concentration for each inhibi-
tor was close to its IC50 value: PD98059 and LY294002
were at 5 μg/ml, SB202190 was at 1 μg/ml and stau-
rosporine was at 40 nM [32]. A strong correlation was
observed between transcript and protein levels, with the
exception of the MEK inhibitor, PD98059, which was
shown to enhance Dex-mediated upregulation of RCAN1-
1 transcript (p < 0.001) while not significantly affecting
RCAN1-1 protein levels. The PI3 kinase inhibitor
LY294002 did not significantly alter RCAN1-1 transcript
upregulation by Dex, but reduced the intensity of RCAN1-
1 protein in Western blotting to about sixty percent of Dex
levels, as estimated by densitometric scanning of two
independent blots (Figure 4B). The p38 MAP kinase
inhibitor SB202190 partially blunted Dex-mediated
upregulation of both RCAN1-1 transcript (p < 0.1) and
protein (to 60%). Staurosporine significantly curtailed
Dex-dependent expression of RCAN1-1  transcript (p <
0.001) and reduced protein expression to basal levels.
These data suggest that Dex-dependent upregulation of
RCAN1-1 is at least partially p38 MAP kinase dependent.
Figure 4C demonstrates the specificity of the inhibitors
used in inhibiting the respective kinase. Lysates prepared
from CEM-C7-14 cells treated with each kinase inhibitor
in the presence of either ethanol or Dex were subjected to
Western blotting with an antibody specific for the PI3
kinase product phospho-Akt in Figure 4Ci. The PI3 kinase
inhibitor LY294002 partially inhibited Akt phosphoryla-
tion, as depicted by the reduced intensity of bands in
lysates of cells treated with 5 μg/ml of LY294002. To eval-
uate the specificity of p38 MAP kinase inhibition by
SB202190, lysates were subjected to a p38 MAP Kinase
assay using a kit (Cell Signaling Technology, cat # 9820)
(Figure 4Cii). p38 MAP kinase from appropriately treated
CEM-C7-14 cell lysates was immunoprecipitated with an
immobilized phospho-p38 MAP kinase antibody fol-
lowed by an in vitro kinase assay using the substrate ATF-
GCs induce RCAN1-1 transcript and protein levels in CEM- C7-14 Cells in a kinase-dependent fashion Figure 4
GCs induce RCAN1-1 transcript and protein levels in 
CEM-C7-14 Cells in a kinase-dependent fashion: 
Panel A: CEM-C7-14 cells were treated for 24 h with the 
indicated kinase inhibitors in the presence of ethanol (E) or 
100 nM Dex (D), total RNA was extracted, and analyzed by 
reverse transcription-Real-time Q-PCR using primers spe-
cific for RCAN1-1. Relative transcript expression in various 
conditions was calculated by the Pfaffl method using β-actin 
as a reference. Panel B: CEM-C7-14 cells were treated with 
the indicated kinase inhibitors in the presence of either etha-
nol (E) or 100 nM Dex (D) for 24 h prior to Western blot-
ting with either RCAN1 or β-actin specific antibodies as in 
Panel A. Densitometric analysis of two independent experi-
ments was performed using ImageJ software, and average 
data are presented below the gel. Panel C: CEM-C7-14 cells 
were treated with the indicated kinase inhibitors in the pres-
ence of either ethanol (E) or 100 nM Dex (D) for 24 h were 
subjected to (i) Western blotting with phospho-Akt specific 
antibody (Cell Signaling Technology, cat # 9271) or (ii) p38 
MAP kinase activity using a kit from Cell Signaling Technology 
(cat # 9820), as described in the methods section.Journal of Molecular Signaling 2009, 4:6 http://www.jmolecularsignaling.com/content/4/1/6
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2. Extent of phospho ATF-2 product was subsequently
detected by Western blotting using a specific antibody.
Figure 4Cii shows that Dex treatment induces p38 MAP
kinase activity, which is blunted in the presence of 1 μg/
ml SB202190.
RCAN1-1 binds to calcineurin A
Lysates from CEM-C7-14 cells treated for 24 h with either
ethanol vehicle or 100 nM Dex were adsorbed to Protein
A-Agarose conjugated to an antibody specific for cal-
cineurin A, the beads were washed with RIPA buffer to
remove non-specifically bound proteins, and subjected to
Western blot analysis using an antibody specific for
RCAN1-1. (Figure 5A). Since Dex treated samples had
greater abundance of RCAN1-1, a greater fraction bound
to and coimmunoprecipitated with calcineurin.
Dex suppresses Calcineurin Phosphatase activity
Interactions between RCAN1 and calcineurin have been
shown to inhibit calcineurin activity [19]. The abundance
of RCAN1-1, and hence the proportion of calcineurin
bound to RCAN1 increases in response to GC treatment of
CEM-C7-14 cells (Figure 5A). In correlation, calcineurin
phosphatase activity, measured by estimating the phos-
phate released from a phosphopeptide substrate, also
decreases in a dose-dependent manner in response to Dex
in CEM-C7-14 cells (Figure 5B). Calcineurin activity in
cells treated with 1 μM Dex was 36% of that in ethanol
treated control CEM-C7-14 cells (p < 0.03). A dose-
dependent decrease in calcineurin activity in response to
Dex was not apparent in CEM-C1-15 cells, however, a
small decrease at 1 μM Dex (67% of control) was
observed, but was not found to be statistically significant.
These data suggest that RCAN1-1 binding may inactivate
calcineurin. Calcineurin has been shown to protect T-cells
from GC-evoked apoptosis [9], and promote T cell sur-
vival [33], hence loss of calcineurin activity may contrib-
ute to GC-evoked apoptosis.
Discussion
Microarray analysis has correlated specific upregulation of
RCAN1 with GC-dependent growth arrest and apoptosis
of leukemic T lymphoblasts and apoptosis of pre B-leuke-
mia cells [6,34]. RCAN1 exists as two major isomeric
forms, RCAN1-1 and RCAN1-4, encoded by alternative
splicing of exons 1 and 4 respectively to common exons 5-
7 [16]. Differential expression of the two RCAN1 isoforms
in response to oxidative and calcium induced stress has
been reported, although both isoforms have been shown
to bind to and modulate calcineurin activity [17,21,35].
Intron 3 contains 15 NFAT binding sites, which enable
Ca2+-dependent upregulation of RCAN1-4; however such
regulation of RCAN1-1 has not been reported [19]. Data
presented here suggest that transcripts specific for total
Calcineurin binds to RCAN1-1 in correlation with loss of  phosphatase activity Figure 5
Calcineurin binds to RCAN1-1 in correlation with 
loss of phosphatase activity: Panel A: CEM-C7-14 cells 
were treated with ethanol vehicle (EtOH) or 100 nM Dex 
(Dex) for 24 h, cell lysates were prepared in RIPA buffer and 
subjected (500 μg protein) to immunoprecipitation with 
either anti-calcineurin A antibody or no antibody, as indi-
cated. Unadsorbed lysates (U; 50 μg protein) or proteins 
bound to Protein A-Agarose (A; entire pellet) were run 
alongside total cell lysates (E; 50 μg protein). Western blot-
ting was performed using RCAN1 antibody (Abgent # 
AP6315c). Panel B: CEM-C7-14 or CEM-C1-15 cells 
treated with 0-1 μM Dex were subjected to a calcineurin 
phosphatase activity assay using a kit (Biomol). Cells were 
lysed in the lysis buffer provided, and were cleared of any 
free phosphate by passing through Micro Bio-Spin P-30 Tris 
chromatography columns (Bio-Rad). Phosphate free lysates 
were incubated with a known calcineurin substrate phos-
phopeptide, RII, and the free phosphate released was meas-
ured using a Malachite Green based assay. Okadaic acid was 
used to inhibit PP1 and PP2A and Okadaic acid and EGTA 
was used to block PP1, PP2A and PP3C (calcineurin) activity. 
To calculate PP3C activity, okadaic acid inhibited activity was 
subtracted from total phosphatase activity. Alternatively, 
okadaic acid and EGTA inhibited activity was subtracted from 
okadaic acid inhibited activity. Phosphate released in nmoles 
was corrected for protein content, measured using the Brad-
ford assay. Data are averages ± SD of two (CEM-C1-15) or 
three (CEM-C7-14) independent treatments, each normal-
ized to the ethanol control.Journal of Molecular Signaling 2009, 4:6 http://www.jmolecularsignaling.com/content/4/1/6
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RCAN1, and isoform 1, RCAN1-1, are selectively upregu-
lated by Dex in CEM-C7-14 cells, but are not significantly
altered in CEM-C1-15 cells, linking RCAN1-1 expression
with GC-evoked apoptosis. A similar selective GC-
dependent upregulation of RCAN1-1 has been reported in
correlation with apoptosis in pre B-leukemia 697 cells
[22].
Interestingly, GC-evoked apoptosis of leukemic CEM-C7-
14 cells is associated with induction of [Ca2+]i levels and is
partially blocked by calcium chelators [31], suggesting
that upregulation of the Ca2+-dependent RCAN1-4 may
contribute to GC-evoked apoptosis. Our data suggest that
Dex does not regulate RCAN1-4. Basal expression of
RCAN1-4 is minimal in both CEM-C7-14 and CEM-C1-15
cells, and Dex concentrations known to induce [Ca2+]i lev-
els selectively in CEM-C7-14 cells [31] failed to signifi-
cantly alter RCAN1-4 expression (Figure 2C). In contrast,
thapsigargin and A23187 selectively upregulated RCAN1-
4, while having negligible effects on RCAN1-1 expression
in CEM-C7-14 cells. Additionally, Cyclosporin A, an
inhibitor of calcineruin signaling, blocked RCAN1-4
upregulation, but had no effect on RCAN1-1 expression.
Differential transcriptional regulation of the two RCAN1
isoforms suggests that they may be involved in distinct
down stream regulatory pathways, as has been reported
recently [36]. RCAN1 has been reported to either inhibit
or facilitate calcineurin activity under different conditions
[23,24]. Calcineurin-dependent upregulation of RCAN1-4
has been implicated as a regulatory loop governing the
extent of cellular calcineurin activity [17,20]. Perhaps
Dex-evoked stimulation of RCAN1-1 and subsequent loss
of calcineurin activity is sufficient to block calcineurin-
dependent upregulation of RCAN1-4 transcription.
Phosphorylation of RCAN1 has been reported to occur
primarily on two serine residues within the FLSIPP motif
encoded by exon 6, with conflicting effects on calcineurin
activity [16]. Phosphorylation of RCAN1-1 transfected in
neuroblastoma cells enhanced its ability to inhibit cal-
cineurin, and decreased its half-life [26]. Conversely, in
cardiac myocytes and CHO-AT1 cells, RCAN1 phosphor-
ylation at the FLISPP motif blocked its ability to bind to
and inhibit calcineurin [25]. Endogenous/physiological
levels of expression of RCAN1, when phosphorylated,
seem to positively regulate calcineurin activity, while
exogenous or over expressed RCAN1 phosphorylation
may enhance negative regulation of calcineurin. Indeed,
phosphorylation of one or both serine residues in a 13-
amino acid synthetic peptide attenuated in vitro inhibition
of calcineurin activity [17]. Lambda phosphatase (a
potent phosphatase with specificity for phospho-Ser/
phospho-Thr and phospho-Tyr) treatment of CEM-C7-14
lysates did not alter the mobility of RCAN1-1 in Western
blotting experiments, suggesting no phosphatase-induced
change in the phosphorylation state of RCAN1-1, or per-
haps the inability of the gel to resolve phospho- vs non-
phospho-RCAN1-1 into distinct bands. Further, phospho-
serine, phosphor-threonine and phospho-tyrosine spe-
cific antibodies were not able to pull down RCAN1-1 in
immunoprecipitation experiments, suggesting that
RCAN1-1 in basal or Dex-stimulated CEM cells may not
by phosphorylated, however further experiments are
needed to substantiate this hypothesis.
Treatment of cells with kinase inhibitors in conjunction
with Dex reduced the abundance of RCAN1-1. The broad
spectrum kinase inhibitor staurosporine completely abol-
ished Dex-dependent induction of RCAN1-1, while the
p38 MAP Kinase inhibitor SB202190 partially inhibited
Dex-dependent upregulation of RCAN1-1. Thus, Dex-
mediated RCAN1-1 induction seems to occur via a
kinase(s)-dependent pathway. This is consistent with ear-
lier reports of a correlation between p38 MAP kinase acti-
vation, phosphorylation of GR at Ser 211, and apoptosis
of CEM-C7-14 cells [37], and MAP kinase mediated
induction of proapoptotic Bim in CEM-C7-14 cells [38].
The precise effect of RCAN1 on calcineurin activity is not
clear. Calcineurin-dependent regulation of gene transcrip-
tion plays an important role in T-cell activation and apop-
tosis. In one study [23] mice lacking RCAN1  showed
altered transcription and caused aberrant expression of
Fas ligand and consequent apoptosis of T helper type 1
cells during their proliferation phase, suggesting that loss
of RCAN1enhances calcineurin activity. In another study,
mouse embryonic fibroblasts deficient in RCAN1 had a
disruption in the activation of calcineruin-dependent
NFAT signaling, suggesting that RCAN1 was required for
calcineurin function [24]. This study also reported
increased apoptosis of CD4+ T cells lacking RCAN1,
although simultaneous deletion of the calcineurin Aβ gene
did not rescue these cells, but rather enhanced apoptosis,
suggesting that RCAN1 functions as a permissive or facili-
tative factor for calcineurin-NFAT signaling. The data pre-
sented in these two reports regarding the effect of RCAN1
knockout are comparable with regard to T helper cell
apoptosis, however are contradictory with regard to inter-
pretation of the effect of RCAN1 on calcineurin activity.
Glucocorticoids and calcineurin have been shown to
inhibit each others apoptotic functions in T cell hybrido-
mas [9], although both agents induce apoptosis. In CEM
cells, our previous studies demonstrate that GC-evoked
apoptosis is associated with activation of the calcium sig-
naling pathway [31], however the calcineurin inhibitor
cyclosporin A induces apoptosis and potentiates GC-
evoked apoptosis (data not shown). Figure 5B demon-
strates that calcineurin activity is repressed by Dex, in cor-
relation with its accumulation in the RCAN1-1 bound
form, in CEM-C7-14 cells. These observations suggest thatJournal of Molecular Signaling 2009, 4:6 http://www.jmolecularsignaling.com/content/4/1/6
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GC-mediated upregulation of RCAN1-1 may inhibit cal-
cineurin activity. Dex-evoked inhibition of calcineurin
activity is significantly lower in CEM-C1-15 cells, which
are refractory to GC-evoked apoptosis, although the low
expression of RCAN1-1 protein made it difficult to deter-
mine whether RCAN1-1 interacts with calcineurin A in
CEM-C1-15 cells.
Conclusion
Based on data presented here, and work done by others,
we conclude that, as illustrated in Figure 6, RCAN1-1 and
RCAN1-4 are regulated by distinct pathways, however,
have a common downstream target in PP3C, which both
isoforms are capable of inhibiting. RCAN1-1 is a target of
the pro-apoptotic GC-response pathway, and its expres-
sion can be blunted by inhibitors of GR activation, such as
the p38 MAP kinase inhibitor SB202190 and stau-
rosporine. By inhibiting calcineurin activity, RCAN1-1 is
inhibiting expression of key survival genes, and therefore
driving the cell towards apoptosis. RCAN1-4, on the other
hand, seems to be a regulatory molecule which keeps
PP3C activity in check.
Methods
Reagents
Dexamethasone (Dex), the calcium ionophore A23187,
Cyclosporin A (CsA) and thapsigargin (TG) were pur-
chased from EMD Biosciences (Madison, WI). Reagents
for reverse transcription (RT) and Real-time QPCR,
including M-MLV reverse transcriptase, oligo(dT)15
primer, RNasin® Ribonuclease inhibitor, dNTP mix, and
Taq DNA polymerase were purchased from Promega Life
Sciences (Madison, WI). SYBR® JumpStart™ Taq ReadyMix
was from Sigma-Aldrich (St. Louis, MO). A polyclonal
rabbit antibody (Cat # AP6315c) directed against the C-
terminal region RCAN1 that recognizes both RCAN1-1
and RCAN 1-4 as 41 kDa and 29 kDa bands respectively,
was from Abgent (San Diego, CA), phosphor-Akt(Ser473)
antibody (Cat # 9271) was from Cell Signaling Technol-
ogy (Beverly MA), calcineurin A antibody (Cat. #C1956)
was from Sigma-Aldrich (St. Louis, MO), CREB antibody
(Cat # sc-186), secondary horseradish peroxidase (HRP)
conjugated anti-rabbit IgG and anti-mouse IgG were from
Santa Cruz Biotechnology (Santa Cruz, CA), the ECL
Western Blotting substrate was from Pierce Biotechnology
(Rockford, IL). P38 MAP kinase assay kit (cat # 9820) was
from Cell Signaling Technology (Beverly MA). Cal-
cineurin Cellular Assay Kit PLUS was from BIOMOL Inter-
national, Plymouth Meeting, PA. Lambda Phosphatase
(Cat. # 14405) was from Upstate Biotechnology, Temec-
ula, CA. Other reagent grade chemicals were purchased
from Fisher Scientific (Pittsburgh, PA) or Sigma-Aldrich
(St. Louis, MO).
Cell Culture
Tissue culture media and components, including fetal
bovine serum (FBS) were purchased from Mediatech
(Washington D.C.). CEM-C7-14 and CEM-C1-15 cells
were kindly provided by Dr. E. B. Thompson (UTMB,
Galveston, TX), and are derivatives of the parental line
CCRF-CEM, obtained from a patient with acute lymphob-
lastic leukemia [39]. Cells were cultured in RPMI 1640
medium supplemented with 5% FBS at 37°C in a humid-
ified 5% CO2 incubator, and were maintained in log
phase by passaging every 3 days. Cell treatments were for
24 h in RPMI supplemented with 5% FBS. All treatment
agents were prepared as 1000× stock solutions in either
ethanol or DMSO. A vehicle alone (0.1% ethanol or 0.1%
DMSO) control was used in all experiments.
RCAN1 mediated regulation of cell proliferation and apopto- sis Figure 6
RCAN1 mediated regulation of cell proliferation and 
apoptosis: Schematic shows that GC-dependent GR activa-
tion and subsequent MAP kinase-dependent phosphorylation 
enables GR binding to GRE sequences on target genes. GR 
alters expression profiles of T-lymphoid cells resulting in a 
net increase in pro-apoptotic gene expression. One of the 
gene that GR induces is RCAN1-1. Increases in [Ca2+]i levels 
triggers the calcium signaling pathway, culminating in the acti-
vation of calcineurin phosphatase (PP3C), which dephospho-
rylates and activates NFAT, causing its nuclear translocation. 
NFAT induces transcription of pro-survival genes, and 
RCAN1-4, which serves as a negative feed-back regulatory 
loop, because it can directly bind to and inactivate calcineurin 
phosphatase. GR-dependent induction of RCAN1-1 also 
causes inhibition of calcineurin, and subsequent down-regula-
tion of pro-survival genes, thus facilitating GR-dependent 
apoptosis of T lymphoid cells.Journal of Molecular Signaling 2009, 4:6 http://www.jmolecularsignaling.com/content/4/1/6
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Real time RT-Q-PCR analysis
Cells were treated at a density of 4 × 105 cells/ml for 24 h
with the appropriate agent, and RNA was extracted from
approximately 1 × 107 cells using the TRIzol reagent (Inv-
itrogen Life Technologies, La Jolla, CA). For first-strand
DNA synthesis, 5 μg of total RNA was reverse transcribed
for 3 h at 42°C in the presence of 0.5 μg of oligo(dT)15, 1
μl (~200 U) of M-MLV reverse transcriptase, 0.5 mM
dNTP mix, and 100 U of RNase inhibitor. PCR amplifica-
tion of transcripts specific for total RCAN1 (RCAN1 All)
and RCAN1-4 was accomplished using forward primers
corresponding to sequences within exon 5 and exon 4,
respectively, and a reverse primer corresponding to exon
7.  RCAN1-1  was amplified using forward and reverse
primers corresponding to sequences within exon 1 and 5
respectively. Primer sequences are shown in Table 1.
Sequences for RCAN1 transcripts were extracted from the
GenBank database (Accession #s NM-004414 and NM-
203418). For real time QPCR, 1 μl of reverse transcription
product was amplified in a Cephid SmartCycler with 125
pmoles of each primer and 12.5 μl of the SYBR® Jump-
Start™ Taq ReadyMix (Sigma, cat # S-4438) in a 25 μl reac-
tion under the following conditions: 30 sec at 94°C, 45
sec at 50°C (55°C for RCAN1-4), 1 min at 72°C. In dupli-
cate reactions PCR was terminated during the exponential
phase and PCR products were resolved on a 1% Agarose
gel in Tris-Borate-EDTA buffer, as per conventional proce-
dures. To normalize between samples, β-actin was used as
a control (primers are shown in Table 1). To quantitate
relative expression levels, the crossing point (CP; or cycle
threshold Ct) values for each sample were used to calcu-
late fold inductions using the Pfaffl method formula[30]:
(Etarget)ΔCPtarget/(Eref)ΔCPref  where  ΔCPtarget = (CPethanol-
CPsample) for RCAN1 and ΔCPref = (CPethanol-CPsample) for
β-actin, and the software LinRegPCR.
Western Blotting
Cells plated at a density of 4 × 105 cells/ml were treated for
24 h with the appropriate agents, and approx. 8 × 106 cells
were harvested, washed and lysed in buffer containing 50
mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, plus a
protease and phosphatase inhibitor cocktail. The amount
of protein in each sample was estimated using the Brad-
ford assay, and 50 μg of each sample was boiled in SDS-
PAGE sample buffer (final composition: 120 mM Tris, 4%
SDS, 20% glycerol, 5% 2-mercaptoethanol, 0.05%
bromophenol blue, pH 6.8) Samples were resolved on a
10% polyacrylamide-SDS gel, and electoblotted on to
PVDF membranes. Membranes were blocked in 10% non-
fat dry milk and incubated sequentially with a RCAN1-
specific polyclonal antibody, AP6315c, and a HRP-cou-
pled anti-rabbit secondary antibody. Membranes were
developed using an Enhanced Chemiluminescence (ECL)
kit from Pierce. To detect the phosphorylation state of
RCAN1-1, cell lysates were treated with 400 U of lambda
phophatase for 20 min prior to loading the gel.
Immunoprecipitation
Appropriately treated CEM-C7-14 cells were washed with
phosphate buffered saline (PBS, pH 7.4) and lysed with
RIPA buffer (final concentration: 150 mM NaCl, 50 mM
Tris pH 8.0, 1% NP-40). Calcineurin antibody was added
in Protein G-Agarose (50% suspension) and incubated
overnight at 4°C on a rotor. Protein G-Agarose was
washed three times with RIPA buffer and cell lysate corre-
sponding to 500 μg of proteins were added and incubated
overnight at 4°C on a rotor. Protein G-Agarose was
washed three times with RIPA buffer before 15.0 μL of 2×
SDS PAGE reagent was added.
p38 MAP Kinase Activity Assay
The p38 MAP kinase assay kit from Cell Signaling Tech-
nology was used to estimate the specificity of kinase
inhibitors in inhibiting MAP kinase activity. Immobilized
phospho-p38 MAP kinase antibody was used to pull
down p38MAP kinase from 500 ug of appropriately
treated CEM-C7-14 cell lysates. The Agarose beads were
washed and resuspended in 25 μl kinase buffer supple-
mented with 200 μM ATP and 20 μg/mL of the p38 MAP
kinase substrate, ATF-2 fusion protein. After incubation at
30°C for 1 h, the reaction was stopped by addition of 5×
SDS-PAGE sample buffer. Western blotting was per-
formed using ATF-2 specific antibody provided in the kit.
Calcineurin Activity Assay
The Calcineurin cellular assay kit Plus (AK-816) from Bio-
mol International (Plymouth Meeting, PA) was used for
measurement of calcineurin activity in CEM cells in
response to 0 to 1 μM Dex. Cells seeded at a density of 5
× 105/ml were treated with Dex for 24 h were lysed in the
manufacturer's lysis buffer containing protease inhibitors.
Cell lysates were passed through size-exclusion micro Bio-
Spin 30 columns (Bio-Rad, Hercules, CA) to remove free
phosphate, and were incubated with RII phosphopeptide,
a known substrate for calcineurin. The phosphate released
was measured by a Malchite Green assay. As per guide-
lines provided in the kit, PP1 and PP2A activity was inhib-
ited by okadaic acid, while EGTA and okadaic acid both
were used to measure PP2C activity. Phosphate released
from these two conditions was subtracted from total
phosphate released in the absence of any inhibitor, to
reveal PP3C activity.
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